Direct answer: Separation anxiety disorder concerns excessive, persistent distress about separation from an attachment figure, with disruption beyond what is expected for development and circumstances. Ordinary childhood separation anxiety is common. Assessment must consider safety, family circumstances and other anxiety problems before deciding what care is needed. Confidence is high in the need for appropriate assessment and safety review, and moderate in this selected summary of clinical care pathways. A supplement substitute is not independently established here. Recommendations are not relabeled as clean, independently replicated trial results (NHS anxiety disorders in children).
Key takeaways
- Separation anxiety disorder concerns excessive, persistent distress about separation from an attachment figure, with disruption beyond what is expected for development and circumstances.
- Attendance alone is an incomplete outcome if a child remains distressed or unsafe.
- Seek prompt professional help when anxiety prevents education, sleep, eating or necessary care.
Table of contents
- Evidence summary
- What it is
- How it works
- The evidence-based treatments
- Supplement and lifestyle evidence
- What works and what does not
- Risks and side effects
- Important interactions
- Who should avoid unsupervised treatment
- Dosage and how to take
- Animal and in-vitro evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
The source roles below are deliberately different. A health-agency explanation can support definitions and a clinical guideline can describe recommended care; neither automatically clears the funding of its supporting trials. This selected review does not provide a newly pooled treatment-effect estimate.
| Question | Source | Funding / conflict | Interpretation and limits |
|---|---|---|---|
| What needs assessment? | NHS anxiety disorders in children | Public institutional education; complete individual disclosures may be unavailable. | Clinical background; no online self-diagnosis. |
| Which care options are discussed? | NIMH psychotherapies; NIMH psychotherapies | Institutional funding checked; every supporting trial has not been screened. | Recommendation/context role; no sponsor-independent effect size claimed. |
| What are medicine and safety limits? | NIMH mental health medications; NIMH suicide warning signs | US publicly funded education. | General precautions; individual decisions require clinical review. |
| Can supplements replace care? | NCCIH anxiety and complementary approaches | Public summary; included-study finances vary. | No independently verified replacement regimen established in this review. |
What it is
A child may find school attendance, sleeping away from a caregiver or ordinary separations very difficult. The fear can include concern that something bad will happen to the person they depend on. NHS guidance distinguishes the usual separation anxiety of young children from persistent anxiety that interferes with everyday life. This guide focuses on that developmental distinction and the route to clinical assessment. It does not use the child-care page to define adult diagnostic criteria. A clinician also asks about the family’s actual situation: illness, loss, bullying, insecure housing or an unsafe school can change the meaning of the behaviour. A parent’s worry is a reason to ask for help, not evidence that the family caused the disorder. (NHS anxiety disorders in children).
How it works
Anxiety can make anticipated separation feel dangerous even when the planned situation has been assessed as safe. Avoiding every separation may bring relief while making future departures harder. This is a clinical formulation, not a universal explanation or an instruction to withdraw reassurance suddenly. Biological vulnerability, experiences and the developmental context can contribute. No routine laboratory result establishes an attachment-related chemical imbalance, and anxiety symptoms do not prove a specific traumatic experience. (NHS anxiety disorders in children).
The evidence-based treatments
The NHS describes psychological care including CBT for anxiety in children. Work can involve the young person, carers and school, using developmentally appropriate goals. An agreed plan considers what help enables participation and what patterns sustain fear. It should address real safeguarding problems directly rather than treating them as irrational worries. Medication is a separate clinical decision, sometimes considered for severe or persistent anxiety; adult instructions should never be copied for a child. This selected source set does not establish a clean comparative treatment-effect estimate specifically for separation anxiety. A provider should explain how the intervention fits the formulation and how progress and adverse effects will be reviewed. (NHS anxiety disorders in children; NIMH psychotherapies).
Supplement and lifestyle evidence
Regular sleep, a balanced diet, manageable activity and support can help a person participate in care. They should be adapted to health and circumstances. General wellbeing benefits do not prove that a routine treats this particular disorder or prevents recurrence. Evidence about stress in healthy volunteers cannot automatically answer a question about a diagnosed clinical condition (NIMH psychotherapies).
This guide establishes no independent supplement replacement for condition-specific assessment and treatment. The public complementary-health summary is used to identify limits and precautions, not to certify the independence of every underlying product study. A manufacturer-funded positive trial, a gift of study material, or an author’s relevant sales interest would exclude that outcome from the strict independent verdict. Unknown finances would remain unknown, rather than be called clean (NCCIH anxiety and complementary approaches).
What works and what does not
Attendance alone is an incomplete outcome if a child remains distressed or unsafe. Relevant progress includes manageable separations, access to education and ordinary activities, and improved family functioning. It is useful to distinguish attachment-related fear from fear of scrutiny, panic, developmental needs or a genuine threat.
Risks and side effects
Seek prompt professional help when anxiety prevents education, sleep, eating or necessary care. Report bullying, abuse or safety concerns explicitly. Threats of self-harm require a safety assessment regardless of whether they occur around separation.
Thoughts of suicide, a plan to act, or inability to keep yourself or another person safe need urgent help. In an immediate danger, contact local emergency services; in the United States, 988 provides crisis support and 911 is for life-threatening emergencies. These numbers are jurisdiction-specific. Tell a trusted person and obtain help rather than relying on an article or supplement. If someone is at immediate risk, do not leave them alone while arranging safe assistance (NIMH suicide warning signs).
Medicines can cause unwanted effects and some require monitoring or a gradual stopping plan. New agitation, marked behavioural change or worsening suicidal thoughts should be reported promptly, particularly around starting or changing an antidepressant. A difficult therapy session should be discussed too; agreed pacing and safety matter (NIMH mental health medications).
Important interactions
Give the clinician or pharmacist the complete list of prescription medicines, non-prescription products, alcohol and recreational substances. Some products act on overlapping systems. NIMH warns that combining serotonergic medicines with certain other drugs or St John’s wort can cause serotonin syndrome. Sedating products can compound impairment. “Natural” does not establish compatibility, and a supplement sold for mood may affect another treatment. Review the actual product and ingredients, rather than assuming a general calming label is enough (NIMH mental health medications).
Who should avoid unsupervised treatment
Children and adolescents, pregnant or breastfeeding patients, older adults with several medicines, and people with complex medical or psychiatric histories need tailored decisions. Anyone with crisis symptoms should avoid substituting self-treatment for urgent assessment. Do not borrow another person’s medicine, copy an adult plan for a child, or use a forum recommendation as an instruction to stop prescribed care. Coexisting conditions may change the risk–benefit balance and the appropriate provider (NIMH mental health medications).
Dosage and how to take
No personal medicine dose, supplement regimen or exposure schedule is provided. Choice, timing, duration, monitoring and stopping depend on the diagnosis, age, other conditions and local instructions. A trial regimen describes what researchers studied, not what every reader should take. Ask the prescriber what benefit to expect, which adverse effects need contact, and how changes will be reviewed. Do not abruptly stop a prescribed medicine without an appropriate clinical plan (NIMH mental health medications).
Animal and in-vitro evidence
Changes in stress hormones, neurotransmitters or behaviour in cells or animals are clues to mechanisms. They cannot establish clinical recovery, functional improvement or safety in a person with this condition. Nor does laboratory activity identify the right human product, formulation or dose. This article excludes animal and cell findings from human efficacy conclusions. Mechanistic plausibility is kept separate from the clinical guidance summarized above.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 3 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Tier describes financial independence; the letter grade describes credibility for the stated use, not treatment potency. The source mix is concentrated in US and UK institutions, with international sources where indicated. Public funding is checked but does not erase individual or trial-level ties. Medicine, device, therapy, app and supplement providers may earn revenue from care; clinicians and institutions also have professional and service incentives. Those interests do not establish misconduct or a payment to this article.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS anxiety disorders in children | Public NHS health-service institution; dated 2019/20 public accounts. Current page-level budget, outside contributors and trial finances not verified. | United Kingdom; England NHS website/service unless the source states another NHS jurisdiction. | Tier 1 public institution, provisional; not an audit of every contributor or underlying study. | B, provisional: patient-safety accountability and transparent service role. Educational simplification, local care pathways and service priorities remain limitations. Funding records cited are dated. |
| NIMH psychotherapies | US NIH/HHS federal appropriations; NIMH budget route. NIMH also accepts donations and bequests through its separate Gift Fund, which can support public information. Page-specific donor allocation and individual contributor finances were not established. | United States; Bethesda, Maryland; federal health research agency. | Tier 1 public appropriations plus disclosed donation route; page-level independence provisional and underlying trial finances vary. | B, provisional: public accountability and scientific reputation reward accuracy. Education is simplified; the institution also promotes its research mission. No blanket trial clearance. |
| WHO mental disorders | Member-state assessed dues and voluntary contributions from states and other partners; WHO funding disclosure. Specific page financing and contributor ties not individually traced. | Switzerland; Geneva headquarters; international UN health agency. | Tier 2, provisional: donor/earmarking interests require scrutiny. | B, provisional: member-state accountability and international scientific reputation; donor priorities and institutional advocacy can influence emphasis. Used for definitions and public-health context. |
| NIMH mental health medications | US NIH/HHS federal appropriations; NIMH budget route. NIMH also accepts donations and bequests through its separate Gift Fund, which can support public information. Page-specific donor allocation and individual contributor finances were not established. | United States; Bethesda, Maryland; federal health research agency. | Tier 1 public appropriations plus disclosed donation route; page-level independence provisional and underlying trial finances vary. | B, provisional: public accountability and scientific reputation reward accuracy. Education is simplified; the institution also promotes its research mission. No blanket trial clearance. |
| NIMH suicide warning signs | US NIH/HHS federal appropriations; NIMH budget route. NIMH also accepts donations and bequests through its separate Gift Fund, which can support public information. Page-specific donor allocation and individual contributor finances were not established. | United States; Bethesda, Maryland; federal health research agency. | Tier 1 public appropriations plus disclosed donation route; page-level independence provisional and underlying trial finances vary. | B, provisional: public accountability and scientific reputation reward accuracy. Education is simplified; the institution also promotes its research mission. No blanket trial clearance. |
| NCCIH anxiety and complementary approaches | US NIH/HHS public appropriations; funding-process documentation. This dated request is not a verified current allocation. NIH gift authority permits conditional and unconditional gifts; actual NCCIH page-specific donor support was not established. | United States; Bethesda, Maryland; federal institution. | Tier 1 institution, provisional; supporting study funding not cleared. | B, provisional: public safety remit and research accountability. Complementary-health research mission and selective summaries remain relevant. Used for limits and safety, not a clean product-effect estimate. |
Frequently asked questions
Is every upset departure a disorder?
No. Age, duration, intensity, circumstances and functional impact matter.
Should a caregiver leave without warning?
Discuss an agreed approach with the clinician and school. Surprise or coercion is not a substitute for an assessed plan.
Does this guide diagnose adults?
No. It explains the developmental distinction and clinical care route; adult symptoms need an adult assessment.
Sources and funding notes
Original source pages were opened for this review, including recommendation text where a guideline is cited. The institution-level funding routes were checked; page-level contributors, guideline declarations and the full financial chain of supporting studies are not all cleared. Public recommendations are therefore reported as guidance, and no drug, device or supplement is assigned an independently verified effect size. Source dates vary and some pages predate the review. This is an educational, selected review rather than an exhaustive systematic search or personal medical advice.
- NHS anxiety disorders in children — Page last reviewed: 15 December 2023
- NIMH psychotherapies — Last Reviewed: February 2024
- WHO mental disorders — Exact source review date not established
- NIMH mental health medications — Last Reviewed: December 2023
- NIMH suicide warning signs — Revised 2023
- NCCIH anxiety and complementary approaches — Last Updated: September 2024
Last reviewed: October 4, 2026.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.